MELBOURNE, Australia (BUSINESS WIRE) Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced today that the Company appointed Ms. Belen Toledo MSc., a biotechnologist specializing in cell regenerative medicine, to evaluate the
AmeriCann, Inc.: AmeriCann Expands Joint Venture Partnership with Bask, Inc. at Massachusetts Cannabis Center
BOSTON, MA / ACCESSWIRE / January 19, 2021
/ AmeriCann, Inc. (OTCQB:ACAN), a cannabis company that develops state-of-the-art cultivation processing and product manufacturing facilities, announced that on January 19, 2021 the Company entered into an agreement to expand the cultivation capacity of its Joint Venture partner, Bask, Inc. ( Bask ).
AmeriCann s flagship project, the Massachusetts Cannabis Center ( MCC ), is located on a 52-acre parcel in Southeastern Massachusetts. The MCC project is permitted for 987,000 sq. ft. of cannabis cultivation and processing infrastructure which is being developed in phases.
Bask, one of the premier vertically integrated Massachusetts operators, commenced operations in Building 1, the MCC s first phase, in February of 2020.
AmeriCann Expands Joint Venture Partnership with Bask, Inc at Massachusetts Cannabis Center saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Propanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy in Pancreatic and Ovarian Cancer Patients
January 18, 2021 GMT
MELBOURNE, Australia (BUSINESS WIRE) Jan 18, 2021
Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced today that the Company has received expressions of interest to evaluate proenzyme therapy as a method to prevent recurrence and metastasis of solid tumors in pancreatic and ovarian cancers. The letters of interest were confirmed by Drs Natalia Luque Caro and Fernando Gálvez Montosa, medical oncologists specializing in pancreatic and ovarian cancers, respectively, from the University Hospital of Jaén, in Granada, Spain. The evaluation will most likely be conducted as separate Phase IIa proof
Propanc Biopharma Analyzes Pancreatic Proenzymes Vs T-Cell Therapy Targeting Solid Tumors Such as Pancreatic, Ovarian & Colorectal Cancers
MELBOURNE, Australia (BUSINESS WIRE)
Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today analyzes pancreatic proenzymes versus T-Cell therapy when targeting solid tumors such as pancreatic, ovarian and colorectal cancers. The analysis is prepared by the Company’s Chief Executive Officer, Mr. James Nathanielsz, in collaboration with joint lead researcher, Professor Macarena Perán, from the University of Jaén, Granada, Spain.
“We are making significant inroads in the way we treat cancer today, but there is a genuine need to continually challenge ourselves to improve the standard of care for many cancer types,” said James Nathanielsz. “At Propanc, we share a vision to develop and commerc